CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 158 filers reported holding CHINOOK THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $21,214,218 | +368714.6% | 552,166 | +122.2% | 0.01% | +233.3% |
| Q1 2023 | $5,752 | -50.2% | 248,454 | -43.6% | 0.00% | -50.0% |
| Q4 2022 | $11,547 | -99.9% | 440,738 | +10.5% | 0.01% | +20.0% |
| Q3 2022 | $7,844,000 | -62.2% | 398,969 | -66.3% | 0.01% | -61.5% |
| Q2 2022 | $20,730,000 | +71.9% | 1,185,233 | +60.8% | 0.01% | +116.7% |
| Q1 2022 | $12,060,000 | +111.0% | 737,139 | +110.3% | 0.01% | +100.0% |
| Q4 2021 | $5,716,000 | -32.6% | 350,444 | -47.3% | 0.00% | -40.0% |
| Q3 2021 | $8,479,000 | +92.7% | 664,476 | +113.3% | 0.01% | +66.7% |
| Q2 2021 | $4,399,000 | -30.9% | 311,561 | -23.9% | 0.00% | -40.0% |
| Q1 2021 | $6,363,000 | +299.9% | 409,487 | +308.1% | 0.01% | +400.0% |
| Q4 2020 | $1,591,000 | – | 100,333 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |